Sublingual Immunotherapy (Allergy Drops & Tablets): Do They Actually Work?

If antihistamines and nasal sprays keep your allergies tolerable but never quite gone, you've probably run into the term "immunotherapy" — treatment that tries to retrain your immune system instead of just blocking its symptoms. Sublingual immunotherapy (SLIT), marketed as "allergy drops" or "allergy tablets," is the needle-free version: allergen extract placed under the tongue, daily, for years. It's real medicine with real trial data behind parts of it — and also a category where marketing runs well ahead of what's actually FDA-approved. This guide separates the two.

This article is for general education and isn't a substitute for a diagnosis or treatment plan from your own physician or allergist.

What Is Sublingual Immunotherapy?

Sublingual immunotherapy works on the same principle as traditional allergy shots (subcutaneous immunotherapy, or SCIT): expose the immune system to gradually increasing amounts of a specific allergen so it stops overreacting to it. Instead of an injection, SLIT delivers the allergen as a liquid drop or fast-dissolving tablet held under the tongue for a minute or two before swallowing. With repeated daily exposure, this appears to shift the immune response away from the allergic (IgE-driven) pattern toward a more tolerant one.

The appeal is obvious: no needles, no weekly clinic visits, and a lower risk of the systemic reactions that make injected immunotherapy require in-office monitoring. The tradeoff is a genuinely long commitment — daily dosing for years, not weeks — and, as the next two sections cover, what's actually approved for use in the U.S. is narrower than the phrase "allergy drops" usually implies.

Do Allergy Drops Work?

Short answer: for the allergens where it's been properly studied, yes — with real caveats about degree and duration.

A Cochrane systematic review pooling multiple randomized, placebo-controlled trials of sublingual immunotherapy for allergic rhinitis found a statistically significant reduction in both symptom scores and medication use compared with placebo PMID: 21154351 — solid evidence that SLIT does something beyond placebo, not just a folk remedy that caught on. Allergen-specific data back this up: a 2017 meta-analysis of randomized controlled trials found sublingual immunotherapy meaningfully reduced symptoms in people with house dust mite-induced allergic rhinitis specifically PMID: 28293928.

Where "actually works" gets more nuanced is magnitude and durability. SLIT's effect size in most trials is real but moderate — noticeably better than placebo, not a cure — and the benefit builds gradually over a full season or more rather than showing up in the first few weeks. It's also allergen-specific: SLIT for grass pollen does nothing for a dust mite allergy, which is why matching the product to a confirmed allergen (via skin or blood testing) matters more here than with an antihistamine you can just try.

Allergy Drops vs. Allergy Shots: SLIT vs. SCIT

If you're choosing between under-the-tongue drops and traditional injected allergy shots, the comparison comes down to three things: efficacy, safety, and convenience.

Efficacy. The comparative evidence is more nuanced than a simple "one is stronger" story. A 2016 review in the Journal of Allergy and Clinical Immunology examined SCIT and SLIT for allergic rhinitis and concluded the two approaches are broadly comparable in efficacy — describing the choice as one of patient "equipoise" — with the decision driven largely by patient preference and practical factors like needle aversion, clinic visits, and treatment burden, rather than a clear efficacy winner PMID: 26853126. Some individual trials comparing the two head-to-head do trend toward a numerically larger effect for SCIT, and an earlier systematic review reached a broadly similar trial-level pattern for seasonal allergic rhinitis while noting direct head-to-head trials remain limited PMID: 23557834. Where that gap appears, it's generally modest rather than dramatic — SLIT isn't a watered-down placebo, just a somewhat gentler tool.

Safety. Here SLIT's case is stronger. Because the allergen is absorbed through oral mucosa rather than injected into tissue, the risk of a severe systemic reaction (including anaphylaxis) is substantially lower with SLIT than SCIT — why allergy shots require in-office observation after every injection, while FDA-approved SLIT tablets are typically taken at home after an initial observed dose.

Convenience. SCIT means a recurring clinic visit, often weekly during buildup and monthly during maintenance, for years. SLIT is a pill or drops taken at home daily — no appointments, but it demands the discipline of not missing doses.

Neither is universally "better" — the choice depends on weighing a modestly larger effect size and clinical supervision (SCIT) against convenience and a better safety profile (SLIT).

FDA-Approved SLIT Tablets vs. Off-Label Allergy Drops (The Honest Distinction)

This is the part of the sublingual immunotherapy conversation that gets glossed over in a lot of marketing, so it's worth being direct about it.

What's FDA-approved: exactly four sublingual immunotherapy products, and all four are dissolvable tablets, not liquid drops. Oralair and Grastek are approved for grass pollen (Oralair covers five grass species; Grastek is specific to timothy grass), Ragwitek is approved for short ragweed, and Odactra is approved for house dust mite allergy. Each went through the standard FDA drug-approval pathway, backed by randomized, placebo-controlled pivotal trials: Oralair's dose-ranging trial for grass pollen PMID: 17935764, Grastek's North American adult trial for timothy grass PMID: 21211643, Ragwitek's pivotal ragweed trial PMID: 23622121, and the phase III trial behind the house dust mite tablet marketed in the U.S. as Odactra PMID: 26292778. If your allergy is confirmed to one of these four allergens, an FDA-approved tablet is the option with the most direct regulatory and trial backing.

What isn't FDA-approved: the liquid "allergy drops" sold by many allergy clinics and telehealth services, often as a custom multi-allergen mix that might include tree pollen, ragweed, dust mite, pet dander, mold, or all of the above in one vial. These use allergen extracts that are themselves FDA-approved — but approved for injection (as SCIT), not under-the-tongue administration. Compounding them into drops and dosing them sublingually is an off-label use. That doesn't automatically mean unsafe or ineffective — allergy drops have been used clinically in parts of Europe for decades, and the Cochrane review above covers drop formulations, not just tablets — but it does mean off-label drops haven't gone through the FDA's product-specific approval process the way Oralair, Grastek, Ragwitek, and Odactra have, and most U.S. insurance, including Medicare, won't cover them as a result.

Telehealth allergy-drop services like Wyndly and Curex have built businesses around this off-label category, typically pairing an at-home allergy test with a custom drop formulation mailed to your door. That convenience is real, and may be reasonable for someone whose relevant allergens (say, mold or pet dander) have no FDA-approved tablet at all — but go in with clear eyes about the off-label status rather than assuming "allergy drops" carries the same regulatory backing as a tablet like Odactra. If dust mite is your primary trigger, our dust mite allergy guide covers environmental steps — like dust mite mattress covers — that work alongside immunotherapy rather than replacing it.

How Long Until Sublingual Immunotherapy Works?

SLIT is not a same-week fix, and setting the right timeline expectation is part of using it well.

Early symptom relief: many people notice some improvement within roughly 8-16 weeks of consistent daily dosing, though this varies by individual and allergen. The pivotal trials for the FDA-approved tablets measured their primary result after patients had dosed through an entire relevant pollen season (or, for the dust mite tablet, a comparable multi-month period) — a more meaningful benchmark than a "week 2" symptom diary.

Full course: the protocols associated with lasting, disease-modifying benefit run about three years of continuous daily dosing — roughly the duration used in the longer-term trials that found effects persisting after treatment stopped, rather than symptoms simply returning once the daily dose was withdrawn.

Stopping early: quitting after a few months because you're "not sure it's working" likely means the trial evidence never had a fair chance to apply — most SLIT trials followed people through a full season or more, and the multi-year course is specifically what's linked to a durable, post-treatment effect.

Who Is a Good Candidate for Sublingual Immunotherapy?

SLIT makes the most sense for a fairly specific profile — worth checking yourself against it before assuming it's the right next step.

Good candidates generally have: allergic rhinitis (or rhinoconjunctivitis) confirmed by skin-prick or blood IgE testing to a specific allergen — guessing from symptoms alone isn't enough, since SLIT is allergen-specific. Ideally that allergen is grass, ragweed, or dust mite, if an FDA-approved tablet is the goal, since those are the only allergens currently covered. A good candidate's symptoms also aren't fully controlled by antihistamines, intranasal steroids, and reasonable environmental control (our best allergy medicines guide covers that first-line toolkit) — or they'd simply prefer to reduce long-term medication reliance. And they're willing and able to take a daily dose, consistently, for roughly three years; SLIT doesn't work as an as-needed or seasonal-only treatment.

Generally not good candidates: people with severe, poorly controlled, or unstable asthma, since the safety data supporting SLIT comes largely from populations with mild-to-moderate or no asthma; anyone with a history of a severe systemic reaction to the specific allergen extract; people on certain medications, including beta-blockers, which can complicate treatment of a rare allergic reaction; and anyone whose primary target is pet or mold allergy, at least if an FDA-approved option is the priority, since no tablet currently covers those allergens — which is where the off-label drops conversation above becomes relevant. If pet dander is your main trigger, our pet allergy guide covers where immunotherapy fits alongside allergen-reduction strategies.

An allergist is really the only one who can confirm candidacy with confidence — testing to pin down the actual trigger is a prerequisite, not an optional step, before starting any immunotherapy.

Side Effects and Safety

The most common side effects are local and mild: itching, tingling, or mild swelling in the mouth, lips, or throat, typically in the first days to weeks of a new dose and easing with continued use. Serious systemic reactions are uncommon with SLIT — meaningfully less common than with injected immunotherapy — but not impossible, which is why the first dose of an FDA-approved tablet is typically taken in a clinician's office under observation, with an epinephrine auto-injector prescribed for home use afterward as a precaution. Throat tightness, difficulty breathing, widespread hives, or swelling beyond the mouth after a dose is a reason to stop and seek medical attention immediately, not to "push through it."

Frequently Asked Questions

Do allergy drops actually work? Yes, for allergens with real trial evidence — grass, ragweed, and dust mite — sublingual immunotherapy meaningfully reduces symptoms versus placebo PMID: 21154351, though benefits build over months and the full effect requires a multi-year course rather than a quick fix.

What's the difference between allergy drops and allergy shots (SLIT vs. SCIT)? Both retrain the immune response to a specific allergen; shots are injected in-office while drops or tablets are self-administered at home. A major review found the two broadly comparable in efficacy, with the choice largely down to patient preference, though some individual trials trend toward a somewhat larger effect for shots; drops carry substantially lower risk of systemic reactions PMID: 26853126 PMID: 23557834.

Are allergy drops FDA-approved? Liquid allergy drops sold by most telehealth and allergy-drop clinics are used off-label — the underlying extracts are FDA-approved for injection, not sublingual dosing. Only four SLIT products are FDA-approved, and all four are tablets: Oralair and Grastek for grass, Ragwitek for ragweed, and Odactra for dust mite.

How long does sublingual immunotherapy take to work? Many people notice some improvement within 8-16 weeks of daily dosing, but the pivotal trials measured benefit after a full pollen season or comparable period, and roughly three years of continuous use is associated with effects that persist after stopping.

Who is a good candidate for sublingual immunotherapy? Someone with allergic rhinitis confirmed by testing to grass, ragweed, or dust mite, whose symptoms aren't fully controlled by medication, and who can commit to daily dosing for several years. Severe or unstable asthma, a history of anaphylaxis to the target allergen, and pet or mold allergy (no FDA-approved tablet exists yet) are reasons it may not be the right fit.

What are the side effects of sublingual immunotherapy? Mostly mild and local — itching or tingling in the mouth or throat — especially early in treatment. Severe systemic reactions are rare with SLIT compared with injected immunotherapy, though the first dose of an FDA-approved tablet is typically given under medical observation.

References

1. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database of Systematic Reviews. 2010;(12):CD002893. PMID: 21154351.
2. Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? Journal of Allergy and Clinical Immunology. 2016;137(2):339-349.e10. PMID: 26853126.
3. Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. Journal of Allergy and Clinical Immunology. 2013;131(5):1361-1366. PMID: 23557834.
4. Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 2007;120(6):1338-1345. PMID: 17935764.
5. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. Journal of Allergy and Clinical Immunology. 2011;127(1):72-80. PMID: 21211643.
6. Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. Journal of Allergy and Clinical Immunology. 2013;131(5):1342-1349.e6. PMID: 23622121.
7. Demoly P, Emminger W, Rehm D, Backer V, Tommerup L, Kleine-Tebbe J. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial. Journal of Allergy and Clinical Immunology. 2016;137(2):444-451.e8. PMID: 26292778.
8. Feng B, Xiang H, Jin H, et al. Efficacy of sublingual immunotherapy for house dust mite-induced allergic rhinitis: a meta-analysis of randomized controlled trials. Allergy, Asthma & Immunology Research. 2017;9(3):220-228. PMID: 28293928.